Crossmark

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

Crossref DOI link: https://doi.org/10.1038/nature14658

Published Online: 2015-07-15

Published Print: 2015-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kondo, Asami

Shahpasand, Koorosh

Mannix, Rebekah

Qiu, Jianhua

Moncaster, Juliet

Chen, Chun-Hau

Yao, Yandan

Lin, Yu-Min

Driver, Jane A.

Sun, Yan

Wei, Shuo

Luo, Man-Li

Albayram, Onder

Huang, Pengyu

Rotenberg, Alexander

Ryo, Akihide

Goldstein, Lee E.

Pascual-Leone, Alvaro

McKee, Ann C.

Meehan, William

Zhou, Xiao Zhen

Lu, Kun Ping
License Information

Text and Data Mining valid from 2015-07-01
More Information

Article History

Received: 17 June 2014

Accepted: 11 June 2015

First Online: 15 July 2015

Competing interests

: Competing Financial Interests. K.P.L. and X.Z.Z. are inventors of Pin1 technology, which was licensed by Beth Israel Deaconess Medical Center to Pinteon Therapeutics. Both K.P.L. and X.Z.Z. own equity in, and consult for, Pinteon. K.P.L. also serves on its Board of Directors. Their interests were reviewed and are managed by Beth Israel Deaconess Medical Center in accordance with its conflict of interest policy.